But also in prostate models due to inhibition of ERG and ETV1, YK-4-279 results in a decrease of the expression of the ERG-target genes PLAU, PLAT and ADAM10 and ETV1-target gene MMP13 [144] associated with in vivo anti-tumor activities [145]. The gene discussed is ETV1; the disease is neoplasm.